Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys $246,906.00 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III bought 12,470 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were bought at an average cost of $19.80 per share, for a total transaction of $246,906.00. Following the transaction, the insider directly owned 996,502 shares in the company, valued at approximately $19,730,739.60. This represents a 1.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Wednesday, January 14th, Group Gp Lp Column III purchased 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 6th, Group Gp Lp Column III acquired 15,100 shares of Surrozen stock. The shares were bought at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III bought 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III bought 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

Shares of Surrozen stock opened at $20.00 on Friday. The company has a market cap of $171.40 million, a P/E ratio of -0.90 and a beta of 0.58. The firm’s 50 day moving average price is $18.70 and its 200-day moving average price is $13.95. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. As a group, equities research analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Surrozen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC boosted its holdings in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after buying an additional 3,424 shares in the last quarter. Geode Capital Management LLC increased its holdings in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares in the last quarter. Acuta Capital Partners LLC raised its position in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after acquiring an additional 8,415 shares during the period. Stonepine Capital Management LLC raised its position in shares of Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after acquiring an additional 47,468 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SRZN shares. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Surrozen presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.